Table 7.
Some key pharmacological aspects of SGLT2 inhibitors
| Drug | Half-life (h) | Dose* | Approximate selectivity (SGLT2 vs SGLT1) |
|---|---|---|---|
| Empagliflozin | 12.4 |
10 mg OD 25 mg OD |
2500 fold |
| Ertugliflozin | 16.6 |
5 mg OD 15 mg OD |
2000 fold |
| Dapagliflozin | 12.7 |
5 mg OD 10 mg OD |
1200 fold |
| Canagliflozin |
10.6 13.1 |
100 mg OD 300 mg OD |
250 fold |
| Sotagliflozin | 29 |
200 mg OD 400 mg OD |
20 fold |
| Remogliflozin | 2 | 100 mg BD | 365 fold |
| Ipragliflozin | 15–16 |
25 mg OD 50 mg OD |
255 fold |
| Tofogliflozin | 6.8 |
20 mg OD 40 mg OD |
2900 fold |
| Luseogliflozin | 9.2–13.8 |
2.5 mg OD 5 mg OD |
1650 fold |
| Bexagliflozin | 5.6 | 20 mg OD# | 2435 fold |
*Doses are described for the respective indications for each agent, as per the regulatory approvals
#Yet to be approved for clinical use